Document is current
Any future updates will be listed below
-
Authors
van den Hoogenhof, Maarten M. G. https://orcid.org/0000-0003-2768-3457
Duran, Javier
Britto-Borges, Thiago
Sequeira, Vasco https://orcid.org/0000-0002-9192-7674
Kemmling, Elena
Konrad, Laura
Schreiter, Friederike https://orcid.org/0009-0002-7405-8064
Lennermann, David C. https://orcid.org/0000-0003-0832-0693
Hartmann, Joshua
Schraft, Laura https://orcid.org/0009-0005-4504-8926
Kornienko, Julia https://orcid.org/0000-0002-7876-230X
Bock, Theresa
Krüger, Marcus https://orcid.org/0000-0002-5846-6941
Maack, Christoph https://orcid.org/0000-0003-3694-4559
Dieterich, Christoph https://orcid.org/0000-0001-9468-6311
Steinmetz, Lars M.
Dewenter, Matthias
Backs, Johannes https://orcid.org/0000-0002-2322-2699
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (HO 6446/1)
Deutsche Forschungsgemeinschaft (SFB1550)
Deutsche Forschungsgemeinschaft (SFB1550)
Health and Life Science Alliance Heidelberg/Mannheim
Deutsches Zentrum für Herz-Kreislaufforschung
BMBF
- License Information
-
More Information
Article History
Received: 23 May 2025
Accepted: 15 April 2026
First Online: 4 May 2026
Competing interests
: V.S. received research funding from Bristol Myers Squibb unrelated to this work. C.M. is an advisory board member for Bristol Myers Squibb, Cytokinetics, Boehringer Ingelheim, AstraZeneca, Servier, Amgen, Novo Nordisk, Bayer, Novartis, Edwards and Berlin Chemie. The other authors declare no competing interests.
